NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $762,266.84 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 29,846 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $25.54, for a total value of $762,266.84. Following the sale, the insider now directly owns 10,656,172 shares in the company, valued at approximately $272,158,632.88. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Thursday, December 26th, Nap B.V. Forgrowth sold 33,438 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.01, for a total transaction of $869,722.38.
• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.49, for a total transaction of $640,614.68.
• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.60, for a total transaction of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total value of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Stock Down 0.1 %

Shares of NewAmsterdam Pharma stock opened at $25.94 on Friday. NewAmsterdam Pharma has a twelve month low of $11.57 and a twelve month high of $27.29. The company has a fifty day moving average price of $22.67 and a 200 day moving average price of $19.42.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently modified their holdings of the stock. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma during the 2nd quarter worth approximately $38,000. Quarry LP raised its stake in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the period. Barclays PLC lifted its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG purchased a new position in shares of NewAmsterdam Pharma in the third quarter valued at $128,000. Finally, XTX Topco Ltd acquired a new stake in NewAmsterdam Pharma during the 3rd quarter valued at $187,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on NAMS shares. HC Wainwright started coverage on shares of NewAmsterdam Pharma in a report on Monday, December 30th. They set a “buy” rating and a $48.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Scotiabank upped their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma has an average rating of “Buy” and an average price target of $38.17.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.